Modality
mAb
MOA
IL-17i
Target
TIGIT
Pathway
Ferroptosis
Crohn'sOCDPompe
Development Pipeline
Preclinical
~Feb 2013
→ ~May 2014
Phase 1
~Aug 2014
→ ~Nov 2015
Phase 2
~Feb 2016
→ ~May 2017
Phase 3
Aug 2017
→ Aug 2031
Phase 3Current
NCT08812722
1,884 pts·OCD
2017-08→2031-08·Terminated
1,884 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-08-085.4y awayPh3 Readout· OCD
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Termina…
Catalysts
Ph3 Readout
2031-08-08 · 5.4y away
OCD
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08812722 | Phase 3 | OCD | Terminated | 1884 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| ARG-3458 | Argenx | Preclinical | RET |